Downloads
Abstract
Background: Treatment of esophageal cancer is multimodal. Choosing the sequence of treatment methods is based on many factors, in which the prognosis whether patients have the response to a specific treatment method or not, from which to choose the appropriate treatment method is very essential. Therefore, finding several factors that are easy to identify, less invasive, cheap, and quickly carried out... with predict ability is a reality in clinical practice. The neutrophil - to - lymphocyte index (NLR index) and platelet - to - lymphocyte index (PLR index) may meet the above requirements. Hence, we do research to determine the role of NLR and PLR indexes in assessing the response to concurrent chemoradiation therapy in esophageal squamous cell carcinoma patients.
Methods: A retrospective descriptive study on 42 squamous cell esophageal cancer patients receiving concurrent chemoradiation therapy with a weekly paclitaxel - carboplatin regimen at 103 Military Hospital from January 2019 to March 2022.
Results: The optimal threshold values of NLR and PLR to distinguish response and non - response in the study group are NLR = 4,37 and PLR = 240. Patients with high NLR index > 4,37 have higher PS, larger T stage, and worse treatment response significantly compared with the group of patients with low NLR ≤ 4,37 with p = 0,0001; 0,006 and < 0,0001, respectively. Patients with high PLR index > 240 had higher PS and worse treatment response significantly than those with low PLR ≤ 240 with p = 0,01 and < 0,0001, respectively.
Conclusion: Pretreatment NLR and PLR index can predict response to concurrent chemoradiation therapy in esophageal cancer patients.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249.
Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 2018;41:210-215.
Vincent Y. DeVita TSL, Steven A. Rosenberg Devita, Hellman, and Rosenberg’s Cancer principles and Practise of Oncology. 11 ed. 2019: Walters Kluwer. 4361.
Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19:2.
Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non- small cell lung cancer. J Transl Med. 2017;15:221.
Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261-6272.
Hà NT. Kết quả hóa xạ trị đồng thời tiền phẫu ung thư thực quản 1/3 giữa-dưới giai đoạn II, III tại bệnh viện TWQĐ 108. Luận văn thạc sỹ y học. 2021.
Ishibashi Y, Tsujimoto H, Hiraki S, Kumano I, Yaguchi Y, Horiguchi H, et al. Prognostic Value of Preoperative Systemic Immunoinflammatory Measures in Patients with Esophageal Cancer. Ann Surg Oncol. 2018;25:3288-3299.
Sun Y, Zhang L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: evidence from a meta-analysis. Cancer Manag Res. 2018;10:6167-6179.
Zhu S, Miao CW, Wang ZT, Peng L, Li B. Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma. Onco Targets Ther. 2016;9:6187-6193.
Zheng Z, Yang C, Cai C, Zhu H. The Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio Predicts Disease-Free Survival in Resectable Esophageal Squamous Cell Carcinoma. Cancer Manag Res. 2021;13:7511-7516.
| Published | 22-07-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 82 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.82.3 | |
| Keywords | Chỉ số NLR, PLR, ung thư thực quản NLR, PLR index, esophageal cancer |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital